RNS Number : 1158D
MaxCyte, Inc.
01 March 2022
MaxCyte, Inc.
("MaxCyte" or the "Company")
Block Listing Return
Gaithersburg, Maryland - 1 March 2022: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling platform technologies for ex-vivo cell engineering, makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:
|
Name of applicant:
|
MaxCyte, Inc.
|
|
Name of scheme:
|
MaxCyte Long Term Incentive Plan
|
|
Period of return:
|
From:
|
1 September 2021
|
To:
|
28 February 2022
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
78,658 ordinary shares of common stock of $0.01 each
|
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
13,000,000 ordinary shares of common stock of $0.01 each
|
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
901,574 ordinary shares of common stock of $0.01 each
|
|
|
|
|
|
|
Name of contact:
|
Amanda Murphy, Chief Financial Officer
Ron Holtz, Chief Accounting Officer
|
|
Telephone number of contact:
|
+1 301 944 1660
|
|
|
For further information, please contact:
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
|
|
|
|
|
|
|
|
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
BLRFFFVLFFITFIF
